Ian M.Pearson

Ian Pearson's practice focuses on food and drug law. Ian advises clients across a range of U.S. Food & Drug Administration (FDA)-regulated sectors, including medical devices, drugs, biologics, and cosmetics

Though his FDA experience is broad and varied, Ian has a distinct focus on the evolving digital health sector and has counseled clients on numerous matters involving mobile medical applications, clinical decision support software, diagnostic algorithms, and other types emerging digital and remote-use devices used for, or complementary to, the delivery of health care services. Ian's FDA work includes advising FDA-regulated companies at the planning, regulatory submission, and post-marketing stages of product development and commercialization, including matters related to product advertising and promotion, good manufacturing practice requirements, FDA inspection and product recall, and managing enforcement actions, among others.

Before joining Jones Day, Ian served for more than seven years in the FDA's Office of Chief Counsel. During that time he was responsible for providing FDA leadership with legal advice on a wide range of regulatory matters and was an FDA lead in the area of digital health, where he assisted agency officials with the development and implementation of the 21st Century Cures Act and associated guidance clarifying FDA's authority to regulate certain types of medical software. He has significant first-hand experience navigating the complexities of the Federal Food, Drug, and Cosmetic Act (FFDCA), as well as the Administrative Procedure Act, Freedom of Information Act (FOIA), Privacy Act, and provisions of the Public Health Service Act applicable to FDA regulatory matters.